The structure of the dopamine D 3 receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology
Abstract
The third-generation antipsychotic cariprazine is a low-efficacy partial agonist of the dopamine D 3 receptor (D 3 R). Here, we report the cryo–electron microscopy structure of cariprazine bound to D 3 R, establishing a framework for understanding ligand recognition in this receptor. We further determine structures of D 3 R in complex with a series of cariprazine derivatives spanning inverse agonists to high-efficacy partial agonists. Integration of structural data with pharmacological profiling and molecular dynamics simulations reveals how subtle chemical modifications translate into distinct functional outcomes. Determinants distinguishing agonism from inverse agonism are well defined, whereas differences among partial agonists arise from small positional shifts of the ligand within the orthosteric binding site. In contrast, the extended binding site primarily modulates ligand stability, affinity, and receptor selectivity. These findings establish a mechanistic link between bitopic ligand architecture and receptor activation, providing a “ligand-centric” view of D 3 R signaling. Leveraging these principles, we designed and validated cariprazine derivatives with enhanced D 3 /D 2 selectivity and partial agonist activity. Together, this work provides a structural and pharmacological blueprint for the rational design of D 3 R-targeting ligands with tailored efficacy and therapeutic profiles.
// Source
Authors: Eliane Yardeni, Dóra Kiss, Julie Sanchez, Keshet Shavit, Dénes Szepesi Kovács, Attila Egyed, Caleb D. Vogt, Supriya A. Gaitonde, Jacqueline Glenn, Meritxell Canals, Michel Bouvier, Amy Hauck Newman, J. Robert Lane, György M. Keserű, Moran Shalev-Benami
Institutions: Université de Montréal, University of Nottingham, Queen's Medical Centre, University of Birmingham, HUN-REN Research Centre for Natural Sciences, Weizmann Institute of Science, National Institute on Drug Abuse, National Research, Development and Innovation Office, National Center for Epidemiology, Institute for Research in Immunology and Cancer